Breaking Finance News

Nektar Therapeutics (NASDAQ:NKTR) price target raised to $23.00, reported today by Brean Capital

In a report announced on Friday September 30, 2016 Brean Capital upped the price target of Nektar Therapeutics (NASDAQ:NKTR) to $23.00 reporting a possible upside of 0.33%.

Only yesterday Nektar Therapeutics (NASDAQ:NKTR) traded -3.17% lower at $17.24. Nektar Therapeutics’s 50-day average is $18.22 and its two hundred day average is $15.72. The last closing price is up 8.83% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. Volume of trade was down over the average, with 457,547 shares of NKTR changing hands under the typical 1,178,010

Performance Chart

Nektar Therapeutics (NASDAQ:NKTR)

With a total market value of $0, Nektar Therapeutics has with a one year low of $9.92 and a one year high of $19.98 .

General Company Details For Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *